公开(公告)号：US20240293586A1

公开(公告)日：2024-09-05

申请号：US18293488

申请日：2022-07-29

Applicant: OSAKA UNIVERSITY

Inventor： Yoshifumi SHIRAKAMI ,  Kazuko KANEDA ,  Yuichiro KADONAGA ,  Tadashi WATABE ,  Atsushi TOYOSHIMA ,  Koichi FUKASE ,  Taku YOSHIYA

IPC: A61K51/08 ,  A61P35/00

CPC classification number: A61K51/088 ,  A61P35/00 ,  A61K2121/00

Abstract: The aims of the present invention are to provide an agent that binds specifically to PSMA, is effective in the treatment and diagnosis of tumors or cancers expressing PSMA, for example, the treatment and diagnosis of prostate cancer, especially castration-resistant prostate cancer (CRPC), further especially metastatic castration-resistant prostate cancer (mCRPC), and does not exhibit side effects due to accumulation in the kidney or salivary glands. The present invention provides a radiolabeled compound represented by Formula (I) or a pharmaceutically acceptable salt thereof:




wherein each symbol is as defined in the description.